Nina DiPrimio, Ph.D.
Affiliations: | 2009 | Pharmacology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Virology BiologyGoogle:
"Nina DiPrimio"Mean distance: 30533.1
Parents
Sign in to add mentor| Richard J. Samulski | grad student | 2009 | UNC Chapel Hill | |
| (Surface loop dynamics of a parvovirus.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Iyer S, Mast JD, Tsang H, et al. (2019) Drug screens of NGLY1 Deficiency worm and fly models reveal catecholamine, NRF2 and anti-inflammatory pathway activation as potential clinical approaches. Disease Models & Mechanisms |
| Lao JP, DiPrimio N, Prangley M, et al. (2018) Yeast Models Of Phosphomannomutase 2 Deficiency, A Congenital Disorder Of Glycosylation. G3 (Bethesda, Md.) |
| Granatosky EA, DiPrimio N, Pickering JRE, et al. (2018) GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts. Journal of Natural Products |
| Xia Y, DiPrimio N, Keppel TR, et al. (2013) The designability of protein switches by chemical rescue of structure: mechanisms of inactivation and reactivation. Journal of the American Chemical Society. 135: 18840-9 |
| Li C, Diprimio N, Bowles DE, et al. (2012) Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. Journal of Virology. 86: 7752-9 |
| DiPrimio N, McPhee SW, Samulski RJ. (2010) Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. Current Opinion in Molecular Therapeutics. 12: 553-60 |
| Johnson JS, Li C, DiPrimio N, et al. (2010) Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. Journal of Virology. 84: 8888-902 |
| Asokan A, Conway JC, Phillips JL, et al. (2010) Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nature Biotechnology. 28: 79-82 |
| Li C, Hirsch M, DiPrimio N, et al. (2009) Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. Journal of Virology. 83: 6817-24 |
| Li W, Asokan A, Wu Z, et al. (2008) Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1252-1260 |